List of Vyvanse drug patents

Vyvanse is owned by Takeda Pharms Usa.

Vyvanse contains Lisdexamfetamine Dimesylate.

Vyvanse has a total of 36 drug patents out of which 0 drug patents have expired.

Vyvanse was authorised for market use on 23 February, 2007.

Vyvanse is available in capsule;oral dosage forms.

Vyvanse can be used as for the treatment of attention deficit hyperactivity disorder (adhd); indicated for the treatment of attention-deficit/hyperactivity disorder (adhd), indicated for the treatment of attention-deficit/hyperactivity disorder (adhd), treatment of attention deficit hyperactivity disorder (adhd) in adults, for the treatment of attention deficit hyperactivity disorder (adhd).

The generics of Vyvanse are possible to be released after 24 August, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(24 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Feb, 2023

(24 days from now)

US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(24 days from now)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(24 days from now)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(6 months from now)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Aug, 2023

(6 months from now)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds
Aug, 2023

(6 months from now)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Aug, 2023

(6 months from now)

Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Market Authorisation Date: 23 February, 2007

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults

Dosage: CAPSULE;ORAL

How can I launch a generic of VYVANSE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in